Smruthi Organic
BSE: SMRUTHIORG · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Smruthi Organic's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Smruthi Organics Limited is an Indian pharmaceutical company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs) and drug intermediates. The company focuses on therapeutic categories including anti-diabetics, anti-hypertensives, and anti-infectives, serving both domestic and international markets.
Business Model
The company generates revenue through the production and sale of APIs and drug intermediates, alongside contract manufacturing services. It leverages two regulatory-compliant manufacturing facilities to supply global markets across Asia, Europe, and Latin America.
Growth Outlook
Growth is driven by the continuous expansion of research and development capabilities to enhance chemical synthesis processes. The company aims to strengthen its product pipeline and maintain its competitive position in the contract manufacturing sector.
Key Risks
- Regulatory Compliance. Failure to maintain international regulatory standards at manufacturing facilities could lead to export bans or loss of market access.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and chemical intermediates can significantly impact profit margins.
- Foreign Exchange Risk. As an exporter to multiple global regions, the company is exposed to currency volatility that may affect financial performance.
- Intense Competition. The API and contract manufacturing market is highly competitive, potentially putting pressure on pricing and market share.
Start your research today
Unlock AI insights, financials, peers and live data on Smruthi Organic and 5,000+ companies — free.
Key Metrics
REVENUE
₹102 Cr
TTM · standalone
NET PROFIT
₹6 Cr
TTM · standalone
EPS
₹4.91
TTM · standalone
RETURN ON EQUITY
7.8%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
11.9%
TTM · standalone
P/E
23.6x
Q4 FY26 · standalone
EV/EBITDA
8.1x
Q4 FY26 · standalone
EBITDA MARGIN
15.9%
TTM · standalone
NET PROFIT MARGIN
3.7%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Smruthi OrganicSMRUTHIORG | ₹160 Cr | 28.46 | 10.25 | -19.1% | 15.9% | 7.8% | 11.9% | +23.6% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Smruthi Organic
BSE: SMRUTHIORG · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Smruthi Organic's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Smruthi Organics Limited is an Indian pharmaceutical company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs) and drug intermediates. The company focuses on therapeutic categories including anti-diabetics, anti-hypertensives, and anti-infectives, serving both domestic and international markets.
Business Model
The company generates revenue through the production and sale of APIs and drug intermediates, alongside contract manufacturing services. It leverages two regulatory-compliant manufacturing facilities to supply global markets across Asia, Europe, and Latin America.
Growth Outlook
Growth is driven by the continuous expansion of research and development capabilities to enhance chemical synthesis processes. The company aims to strengthen its product pipeline and maintain its competitive position in the contract manufacturing sector.
Key Risks
- Regulatory Compliance. Failure to maintain international regulatory standards at manufacturing facilities could lead to export bans or loss of market access.
- Raw Material Price Volatility. Fluctuations in the cost of key starting materials and chemical intermediates can significantly impact profit margins.
- Foreign Exchange Risk. As an exporter to multiple global regions, the company is exposed to currency volatility that may affect financial performance.
- Intense Competition. The API and contract manufacturing market is highly competitive, potentially putting pressure on pricing and market share.
Start your research today
Unlock AI insights, financials, peers and live data on Smruthi Organic and 5,000+ companies — free.
Key Metrics
REVENUE
₹102 Cr
TTM · standalone
NET PROFIT
₹6 Cr
TTM · standalone
EPS
₹4.91
TTM · standalone
RETURN ON EQUITY
7.8%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
11.9%
TTM · standalone
P/E
23.6x
Q4 FY26 · standalone
EV/EBITDA
8.1x
Q4 FY26 · standalone
EBITDA MARGIN
15.9%
TTM · standalone
NET PROFIT MARGIN
3.7%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26